Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.56 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.54 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.49 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079654 | 0.90 | FLT3 (0.55) | FLT3MAPK1MAPK3ITKCSNK1D | |
| SCHEMBL13812053 | 0.86 | KDM4E (0.57) | FLT3MAPK1KDM4EHSD17B10 | |
| SCHEMBL13812159 | 0.84 | ALDH1A1 (0.60) | FLT3KDM4ELMNAHSD17B10 | |
| SCHEMBL8258855 | 0.83 | TRPA1 (0.64) | FLT3TRPA1MAPK1MAP3K5MAPK3 | |
| SCHEMBL13812271 | 0.83 | TRPA1 (0.53) | FLT3TRPA1MAPK1MAP3K5MAPK3 | |
| SCHEMBL4089658 | 0.82 | BTK (0.61) | FLT3MAPK1ITKKDM4ELMNA | |
| SCHEMBL5372669 | 0.82 | MAP2K4 (0.57) | FLT3MAPK1MAP3K5ITKBTK | |
| SCHEMBL13877029 | 0.80 | TRPA1 (0.48) | FLT3TRPA1MAPK1MAP3K5KDM4E | |
| SCHEMBL2867128 | 0.79 | MAPK1 (0.58) | FLT3MAPK1MAPK3CSNK1D | |
| SCHEMBL5379401 | 0.78 | MAPK1 (0.59) | FLT3TRPA1MAPK1MAP3K5MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | FLT3 1140/4885TRPA1 144/4885MAPK1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.